Regeneron’s COVID-19 antiviral mAb cocktail reduces viral load in outpatients

Initial data from Regeneron’s COVID-19 outpatient trial of its antiviral mAb cocktail suggest the patients who will benefit most are those who didn’t mount an antibody response or who have high viral loads.

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), which presented the data from the double-blind Phase I/II/III trial of REGN-COV2 late Tuesday, has already begun discussing the data with regulators to inform next steps, which include readouts from trials to treat hospitalized patients and to prevent the disease in individuals with SARS-CoV-2-positive household contacts...